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ABSTRACT 
Objectives: Hemorrhagic or hypovolemic shocks accounts for a large portion of civilian and military trauma deaths due to life-threatening blood 
loss which requires intravenous fluid infusion to prevent essential deficiencies of fluids. However, at low temperature (-150
Methods: FRIV formulations were developed using standardized ringer lactate (RL) formulation protocol, in which varying concentrations of 
ethanol and glycerol were added to induce desired physiochemical properties. Efficacy of FRIV was evaluated in terms of survival percentage of 
hemorrhagic animal models (Swiss albino strain mice). Acute toxicity studies were carried out through an infusion at dose levels (0, 20 and 40 
ml/Kg b. wt.).  
C) fluid bottles freeze 
out and can not be used in emergency. In view of that, objective of the present work is to develop a freezing resistant intravenous formulation 
(FRIV) and its in vivo safety and efficacy evaluation.  
Results: In vitro data showed that optimized FRIV (F-10) takes more time (360 ± 21 min) for freezing and less time in thawing (50 ± 4.50 min) in 
comparison to control which takes (110 ± 15 min) in freezing and (80 ± 7.25 min) in thawing. Formulations were found to be stable and sterile up to 
six months. In vivo efficacy data showed ≥ 75% survival in animals infused with FRIV as compared to control group in hemorrhagic animal models 
and no treatment related toxic effects of optimized formulation in terms of hematological, serum biochemistry and histopathological analysis.  
Conclusion: Pre-clinical safety and efficacy data of the present study indicated that developed FRIV formulation could be used for fluid recovery 
during the hemorrhagic shocks conditions in the combat scenario. 
Keywords: Freezing Resistant Intravenous Fluid, Infusion, Pre-clinical, Serum biochemistry, Histopathology. 
 
INTRODUCTION 
Hemorrhagic or hypovolemic shocks accounts for a large portion of 
civilian and military trauma deaths, results due to life-threatening 
blood loss or decrease in blood pressure [1-3]. This also leads to 
tissue ischemia, shock, insufficient oxygen delivery for cellular 
metabolism [4]. Hemorrhage is responsible for more than 40% of 
trauma mortality. Up to 56% out of them occurs during the pre-
hospital period [5]. Mortality is linked directly to severe blood loss 
or indirectly due to multiple organ failure. Specifically, loss of 
pulmonary function, renal, hepatic, and gastrointestinal is common 
after hemorrhagic shock [6]. Insufficient fluid resuscitation as well 
as catecholamines stabilize the cardiovascular function, 
uncontrolled hemorrhagic shock occurs which is also life-
threatening [7]. Although resuscitation of shock induced alteration 
in morbidity and mortality involves an appreciation for the quantity 
of fluid loss that might be required, however it is difficult to measure 
the amount of blood loss in most situations [8-11]. To overcome this 
problem instant administration of intravenous (IV) fluids therapy 
plays a vital role.  
Intravenous fluid infusion in critical injuries aims to prevent 
essential deficiencies of fluids, to overcome hypovolemia, replace 
lost electrolytes to correct dehydration. It is also used as a means of 
treating various diseases, blood transfusion and act as a vehicle for 
the excretion of waste products and redundant metabolites [12]. 
Intravenous route is the fastest way to deliver fluids and 
medications throughout the body as compared with other routes of 
administration and has been widely accepted therapy as a mean of 
parenteral administration. More than 80% of hospitalized patients 
receive IV fluid infusion at some point during their admission [12, 
13]. The intracellular fluid volume in the body system is a function of 
the health of the cells and therefore it can only be indirectly affected 
by fluid infusion [11]. Body electrolytes and extracellular fluids are 
tightly regulated by neural, humoral and renal mechanism to 
maintain osmolarity of extracellular fluid and normal extra cellular 
volume. About two third of total body water is intracellular fluid 
which is distributed into intracellular, interstitial, and intravascular 
compartments [14]. Each of the compartments has a fixed volume 
and electrolyte composition that must be considered in the 
development of a resuscitation strategy. 
Three main types of intravenous fluid that are used to restore and 
maintain body systems during shock resuscitation includes, blood 
and blood products, colloidal fluids, and crystalloid solutions. 
Crystalloids are true aqueous solutions of mineral salts and are often 
associated with physical characteristics which affect the balance of 
these fluids in two of the body fluid compartments: intravascular 
and interstitial making crystalloids to pass readily through biological 
membranes [15, 16]. Crystalloids used for IV infusion should be 
isotonic so that they do not cause a significant shift of water 
between the blood vessels and cells [2, 17]. Intravenous fluids are 
sterile aqueous solutions or emulsions having water as the 
continuous phase. They are free from pyrogens or microbial 
contamination, usually made isotonic with blood and do not contain 
any added antimicrobial preservatives that can be observed on 
visual inspection with the naked eye. The intravenous fluid should 
have the purpose specific formulation, balanced physiochemical 
composition to dissolve solutes called electrolytes (charged particles 
such as sodium, potassium, and chloride). 
At high altitude (above 10,000 feet) due to sub-zero temperature 
intravenous fluids freeze out and cannot be used in trauma / 
emergency scenario due to the longer time (hrs) taken in thawing or 
defreezing. In case of hemorrhagic shocks,/ injuries immediate 
administration of fluids is necessary for the quick management of 
electrolytes concentration in the body fluid for maintenance of 
homeostasis. First 60 min following a traumatic injury has been 
recognized as vital to save lives of the patient, which depends on the 
quick administration of the IV fluids. Apart from more thawing time, 
sub-zero temperature also causes denaturation or degradation of 
the number of essential components of the injectables making them 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491              Vol 6, Issue 10, 2014 
Innovare 
Academic Sciences 
Amit et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 10, 490-496 
491 
unusable. In view of that, objective of the present study is 
development and characterization of a freeze resistant intravenous 
(FRIV) formulation for high altitude. The developed FRIV will be 
able to replace the fluid/ blood loss from the body with reduced 
thawing time in addition to survival efficacy. 
MATERIALS AND METHODS 
Chemical and Reagents  
Sodium chloride, potassium chloride, calcium chloride, lactic acid 
and analytical grade (AR) reagents were purchased from Merck Ltd. 
India. Ringer Lactate was procured from Denis Chem Lab Ltd., 
Ahmedabad, India. Glycerol was purchased from SD Fine Chemical 
Ltd, Mumbai, India. All other chemicals were of AR grade and used as 
obtained. 
Experimental Animals 
Male Swiss albino strain mice, weighing 28 ± 2g from the animal 
house facility of the Institute were used for the study. All animal 
experimental protocols were approved by the Institutional Animal 
Ethical Committee (IAEC). Experimental animals were housed in 
polypropylene cages in groups of six mice per cage and kept in a 
room maintained at 25 ± 20
Methods 
C with a 12h light/dark cycle, and were 
acclimatized for a week before conducting an experiment. They were 
given free access to standard laboratory animal feed (Golden Feed 
Laboratory. Delhi, India) and water ad libitum. 
Preparation of freezing resistant intravenous (FRIV) 
formulations  
Different FRIV fluid formulations based on Ringer lactate were 
prepared using the standard protocol and varying concentration of 
ethanol and glycerol was also added. Briefly, the solvent used for 
preparation of FRIV fluids formulations was water for injection. 
After addition of different constituents of ringer lactate (Calcium 
Chloride, Potassium Chloride, Sodium Chloride, and Sodium Lactate) 
in the given concentration as per British Pharmacopeia 2007, 
ethanol (0-4%), and glycerol (0-20%) were also added and mixed 
thoroughly using mechanical stirrer at 100 rpm for 30 min at 25 0C 
[18]. The formulations thus prepared were evaluated for clarity 
against alternate light and black backgrounds. After aseptic 
preparation the fluids were filtered through 0.22 μm membrane 
filter (Acrodisc®
In-vitro characterization  
, Pall Corporation, USA) and thereafter transferred 
to the pre-sterilized glass containers.  
Evaluation of Freezing Resistant Characteristics  
Fourteen (14) different formulations were prepared and evaluated 
for their freezing and thawing properties. Formulations were filled 
in plastic bags used for IV fluid storage and kept at sub-zero 
temperature (-20 ± 0.1 0C) in refrigerating circulating bath (RW-
1025G, JEIO TECH, Korea), to observe freezing time. Complete frozen 
bottles were taken out and kept at room temperature (250
Physiochemical Analysis 
C) to 
observe thawing time. 
Freezing and Thawing Stability 
After six repetitive cycles of freezing and thawing, formulations 
were evaluated for changes in their pH, color, and aggregation if any, 
to confirm their stability (British Pharmacopeia, 2007). Briefly; 10 
milliliters (ml) of the solution into a 20 ml colorless ampoule was 
filled and sealed, and used as the sample. Separately, 10 ml of the 
solution was put into a 20 ml colourless ampoule and sealed which 
was wrapped in aluminum foil to protect completely from light, and 
used as the control. The sample and control were exposed to the 
light source for an appropriate number of hours. Samples were then 
analyzed for physical appearance, pH, and color. 
Determination of pH 
The pH of developed formulations was measured using a pH meter 
(Microprocessor pH system, Punjab, India) for analysis of acidic or 
basic nature of the fluids. pH of the formulations was also evaluated 
after repetitive freezing and thawing to establish stability of the 
formulation. 
Microscopic observation 
The slides of optimized fluid formulation were prepared and 
observed under the microscope (Olympus BX 60) for any 
physiochemical change or contamination in the formulation at 
different time intervals (1, 3, and 6 months) so as to confirm the 
stability of developed fluid formulation. 
In-vivo evaluation of FRIV formulation 
Efficacy evaluation 
In vivo efficacy evaluation studies of developed FRIV fluid 
formulation was carried out on hemorrhagic animal models. 
Hemorrhagic shock was induced withdrawing the blood (1 ml) from 
retro-orbital plexus of the animals. Twenty-four Swiss albino strain 
male mice were selected and randomly divided into 3 groups, 8 
animals in each. Animal groups were designated as group I, group II, 
and group III. The animals of group I, was kept as control and no 
treatment was given while animals of group II and III were treated 
with intravenous infusion of Ringer Lactate and developed FRIV 
formulation respectively (equal to the volume to the total blood 
withdrawn) instantly after blood collection using a calibrated 
portable infusion pump (Pilot E, A2 India 01, Fresenius vial SA). A 
27G X19 mm Top Winged Infusion Set (Meditop Corporation (M) 
SDN BHD Malaysia) was inserted into tail vein for infusion of fluids. 
Thereafter, clinical sign and symptoms of toxicity and survival 
studies were observed in all the animals [19]. 
Acute toxicity study  
Eighteen (18) Swiss albino strain male mice weighing 28 ± 2g were 
selected and randomly divided into three groups of six animals in 
each. The animals groups were designated as group I, group II, and 
group III. The animals of group I served as control and received no 
treatment. Group II and III animals received a single dose of 
optimized FRIV fluid (20 and 40 ml/kg b. wt.) respectively using a 
calibrated portable infusion.  
A 27GX19 mm, Top Winged Infusion was inserted into tail vein for 
infusion of FRIV fluid. Animals were observed prior to infusion, 
throughout the infusion process, and again approximately 1h after 
the infusion process. Untreated control mice were weighed and 
returned to their cages they were observed before and after other 
mice were injected. Animals were observed daily after dosing up to 
14 days for any clinical sign of toxicity and mortality [20]. At 14th 
day of IV infusion experimental animals were sacrificed and 
dissected for further evaluation. 
Observations 
Gross pathology 
The animals were observed for any changes in skin, fur, eyes, 
mucous membranes, autonomic, central nervous systems, 
somatomotor activity and behavior pattern. Attention was also 
directed toward observations of tremors, convulsions, salivation, 
diarrhoea, lethargy, and sleep if any.  
Body weight, food and water intake 
All animals were observed at least twice a day and their body weights, 
feed, and water intake were recorded daily throughout the experiment. 
Hematological analysis 
The animals were fasted overnight prior to necropsy and blood 
collection. Blood was collected by cardiac puncture in vials 
containing EDTA for immediate analysis of hematological 
parameters. Standard hematological parameters like red blood cells 
(RBCs), white blood cells (WBCs), erythrocyte sedimentation rate 
(ESR), P/C ratio, hemoglobin (Hb), hematocrit (HCT), mean 
corpuscular volume (MCV), mean cell hemoglobin (MCH) and 
platelets (PLT) counts were analysed using hematological automatic 
analyzer (Roche Integra, 400 Plus, Diagnostic Systems). 
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Serum biochemistry analysis 
Blood samples for biochemical investigations were collected in plain 
tubes and centrifuged at 4000 rpm at 4°C for 10 min to obtain the 
serum. Serum glutamic oxaloacetic transaminase (SGOT), serum 
glutamic pyruvic transaminase activities (SGPT), alkaline phosphatase 
(ALP), protein, albumin, globulin, A/G ratio, urea, uric acid, and 
creatinine levels were estimated using the reagent kit of Randox 
Laboratory Ltd, UK in an automated analyzer (DREL 3000 HACH). 
Organ/ body weight ratio analysis 
After detailed gross necropsy examination, vital organs (heart, 
kidneys, liver, lungs, and spleen) were collected carefully for 
microscopic examine. Further their weights were analysed in 
relation to total body weight. 
Histopathological analysis 
The tissue samples of different vital organs viz; heart, kidney, liver, 
lung, and spleen were collected from all the animals and preserved 
in 10% buffered neutral formalin. They were adequately sliced 
wherever necessary. After a minimum of 24h fixation, they were 
sampled and processed by conventional methods [21], paraffin 
blocks were made and 5μm size paraffin sections were stained with 
hematoxylin and eosin [22]. The sections were deparaffinized using 
xylene and ethanol. The slides were washed with phosphate buffer 
saline (PBS) and permeabilized with permeabilization solution 
(0.1M citrate, 0.1% Triton X-100). Tissue histology was evaluated 
and microscopic changes were analyzed under a light microscope 
and compared with control. 
Statistical analysis  
Numerical data from experiments are presented as Mean ± SD. 
Differences between groups were analyzed following one way 
ANOVA using Dunnett’s test and minimum criterion for statistical 
significance was set at p < 0.05 for all comparisons. 
RESULTS 
Preparation of FRIV fluid formulations 
Fourteen (14) different types of FRIV formulations were developed 
as shown in Table 1. Physical properties of the developed 
formulations were also observed by naked eye any change in 
transparency and texture of the formulation was observed with 
change in the concentration of ethanol and glycerol. 
 
Table 1: Concentrations of different constituents present in FRIV fluid formulations prepared. 
Formulation No. Different constituents in FRIF fluid formulation 
Ringer Lactate Ethanol Glycerol Physical Appearance 
F-1 Normal Saline - - Clear, Transparent 
F-2 + 1% - Clear, Transparent 
F-3 + - 5% Clear, Transparent 
F-4 + 2% - Clear, Transparent 
F-5 + 4% - Clear, Transparent 
F-6 + - 10% Clear, Transparent 
F-7 + - 15% Clear, Transparent 
F-8 + - 20% Transparent with phase separation 
F-9 + 2% 10% Clear, Transparent 
F-10 + 2% 15% Clear, Transparent 
F-11 + 2% 20% Transparent with phase separation 
F-12 + 4% 10% Transparent with phase separation 
F-13 + 4% 15% Transparent with phase separation 
F-14 + 4% 20% Transparent with phase separation 
 
Table 2: Time taken in complete freezing and thawing by different FRIV fluid formulations. 
Formulation 
No. 
Initiation of freezing 
Time (min) 
Completion of freezing Time (min) Thawing Time (min) 
F-1 50 ± 4.50 110 ± 15.00 80 ± 7.25 
F-2 60 ± 3.64 150 ± 11.50 60 ± 6.40 
F-3 70 ± 5.24 160 ± 14.60 55 ± 6.25 
F-4 90 ± 6.40 180 ± 16.20 45 ± 5.54 
F-5 120 ± 10.50 210 ± 18.75 35 ± 5.20 
F-6 210 ± 14.25 315 ± 23.10 70 ± 7.90 
F-7 270 ± 20.60 375 ± 25.45 50 ± 4.94 
F-8 300 ± 21.85 405 ± 28.00 45 ± 4.52 
F-9 210 ± 13.50 290 ± 22.70 60 ± 5.04 
* 300 ± 19.75 F-10 360 ± 21.00 50 ± 4.50 
F-11 265 ± 20.25 350 ± 21.30 45 ± 4.74 
F-12 225 ± 14.30 300 ± 19.65 60 ± 5.94 
F-13 300 ± 20.90 405 ± 26.40 40 ± 4.34 
F-14 345 ± 22.48 465 ± 28.85 35 ± 3.85 
*
 
 Optimized Freezing Resistant Intravenous Formulation 
In-vitro characterization 
Evaluation of Freezing Resistant Characteristics 
Freezing and thawing time of developed FRIV fluid formulations at 
sub-zero temperature (-200C ±0.10
Increase in the freezing time and decrease in the thawing time was 
observed uniformly by an increase in the concentration of ethanol 
and glycerol. 
C) are shown in Table 2. Freezing 
and thawing cycle was repeated six times and depression in the 
freezing point was observed in all the developed formulations. 
Freezing time increases from ~110 min to ~465 min after addition 
of 4% ethanol and 20% glycerol.  
Physical Analysis  
Stability 
After six repetitive freezing/ thawing cycles of developed 
formulations no significant change in physiochemical properties 
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(precipitation, pH and color) of the formulations were observed in 
comparison to control IV fluid.  
Evaluation of pH 
Repetitive freezing/ thawing of developed formulations has not 
showed any effect on the pH of developed FRIV formulations and 
found to be between 6.5 ± 0.3.  
Microscopic observation 
No microbial contamination was observed up to six months. The 
microscopic evaluation of developed formulation was carried out at 
0, 1, 3, and 6 month time interval.  
In-vivo efficacy evaluation 
The survival of animals of different groups has been shown in Fig. 1. 
All animals of group I were found dead within 24 hours of blood 
withdrawn, ~ 25% of animal survival rate was observed in the 
animals of group II, which was infused with normal ringer lactate 
intravenous fluid. On the other hand, group III animals infused with 
developed FRIV formulation showed more than 75% survival rate. 
 
Fig. 1: Efficacy evaluation of FRIV fluid formulation intravenous 
infusion on hemorrhagic shocked animals. Values are 
expressed as mean ± S. D; (n=8). 
Acute toxicity studies 
Gross pathology 
No mortality and morbidity or any signs of behavioural changes or 
toxicity were observed up to 14-days period after intravenous 
infusion of dose levels of 20 and 40 ml/kg body weight. 
Morphological characteristics (fur, skin, eyes, and nose) appeared 
normal. No tremors, convulsion, salivation, diarrhea, lethargy or 
unusual behaviours such as self-mutilation, walking backward and 
so forth were observed; gait and posture, reactivity to handling or 
sensory stimuli, grip strength were all normal.  
Food, water intake and body weight analysis 
No significant changes were observed in weight of treated groups as 
compared to control (Fig. 2). No significant difference was observed 
in test group of experimental animals in comparison to the control 
group of animals in terms of nutritional status/ feeding habits. Body 
weights of treated animals increased and there were no changes as 
compared to control. 
 
Fig. 2: Body weight variations in experimental animals treated 
with FRIV fluid formulation infusion during acute toxicity study. 
Values are expressed as mean ± S. D; (n=6). 
 
Hematological analysis 
As shown in Table 3, no significant changes were observed in 
hematological parameters in all the treated groups as compared to 
control group animals. 
 
Table 3: Hematalogical evaluation of experimental animals treated with different dose of FRIV fluid formulation. 
Hematological 
Parameters 
Group I Group II Group III 
Average ± SD Average ± SD Average ± SD 
Hb (gm/dl) 12.17 ± 1.38 11.067 ± 1.53 12.36 ± 1.42 
WBC (103 10.84 ± 1.88 /µL) 9.96 ± 1.94 10.78 ± 1.96 
ESR(mm/1sthr) 16.00 ± 1.46 19.66 ± 1.52 12.66 ± 1.49 
P/C 1.43 ± 0.058 1.653 ± 0.045 1.43 ± 0.208 
MCV (fl) 41.41 ± 2.58 42.30 ± 2.62 41.71 ± 2.618 
MCH (pg) 30.11 ± 1.12 30.37 ± 1.16 30.35 ± 1.32 
MCHC (g/dl) 33.13 ± 2.431 33.43 ± 2.516 34.15 ± 2.551 
RBC (106 9.45 ± 1.235 /µL) 9.63 ± 1.353 8.92 ± 1.372 
HCT (%) 36.00 ± 1.400 35.33 ± 1.528 36.06 ± 1.462 
*Group I: Control; Group II: 20 ml/Kg b. wt., and Group III: 40 ml/kg b. wt. infusion of developed FRIV formulation. Values are expressed as mean ± 
S. D; (n=6) and p > 0.05; group II and III versus group III. 
 
Table 4: Serum biochemical parameters in blood samples of experimental animals treated with different dose of FRIV fluid formulation. 
Serum biochemistry parameters Group 
Group I Group II Group III 
SGOT/AST (IU/L) 88.33 ± 7.53 92.30 ± 8.50 94.20 ± 8.75 
SGPT/ALT (IU/L) 57.00 ± 4.65 59.67 ± 5.59 60.67 ± 5.06 
ALP (IU/L) 72.00 ± 3.96 69.67 ± 4.25 76.00 ± 4.61 
Protein (g/dl) 7.13 ± 1.15 7.43 ± 1.32 7.90 ± 1.36 
Albumin (g%) 3.37 ± 0.65 3.55 ± 0.62 3.76 ± 0.73 
Globulin (g%) 2.40 ± 0.32 2.52 ± 0.35 2.70 ± 0.34 
A/G 1.52 ± 0.16 1.49 ± 0.15 1.56 ± 0.16 
Urea (mg/dl) 31.00 ± 3.42 25.00 ± 3.34 29.00 ± 3.66 
Uric acid (mg/dl) 8.00 ± 1.20 7.64 ± 1.28 7.38 ± 1.18 
Creatinine (mg/dl) 0.52 ± 0.040 0.56 ± 0.042 0.62± 0.046 
*Group I: Control; Group II: 20 ml/Kg b. wt., and Group III: 40 ml/kg b. wt. Infusion of developed FRIV formulation. Values are expressed as mean ± 
S. D; (n=6) and p > 0.05; group II and III versus group III. 
 
 
Serum biochemistry analysis 
Serum biochemistry parameters are shown in Table 4. There were 
no significant changes in treated animals as compared to control 
group animals. 
Organ/ body weights ratio analysis 
No statistically significant differences in organ/ body weights ratio 
of vital organs (heart, kidney, liver, lung, and spleen) of 
experimental animals as compared to control group were observed 
as gave in Figure 3. 
 
 
Fig. 3: Organ/ body weight ratio determination of vital organs 
of experimental animals treated with FRIV fluid formulation. 
Values are expressed as Mean ± S. D; (n=6). 
 
Histopathalogical analysis 
At necropsy no abnormalities were detected in pathological 
examinations of the tissues during microscopic examination of vital 
organs in comparative histology of tissues of control and test 
animals. As shown in Figure 4, Infusion of FRIV formulation did not 




 Fig. 4: Histological micrographs of different vital organs of 
experimental animals treated with FRIV fluid formulation 
(Magnification: 20X). 
DISCUSSION 
Hemorrhagic shock remains one of the leading causes of death in 
battlefield [4]. It is critical to provide medical aid with real time 
monitoring of soldiers in traumatic injuries. The excessive loss of 
fluid leads to the dysfunction of immune cells, resulting in tissue 
damage and finally organ failure [23, 24]. Intravenous fluids are 
pharmaceutical products that are administered intravenously to 
recover fluid loss. At high altitude, due to the extreme low 
temperature the intravenous fluid gets freeze and is not used in case 
of emergency.  
We have formulated and optimize freezing resistant intravenous 
(FRIV) fluid which remains in liquid form even at sub-zero (-20°C) 
temperature. Freezing resistant property in developed intravenous 
fluids was induced by adding variable concentration of ethanol (0-
4%) and glycerol (0-20%). It was observed that, freezing resistant 
property increases with increase in the concentration of the ethanol 
and glycerol. It was due to the hindrance in the hydrogen bonding 
developed after addition of crystalloids and increases with increase 
in concentration of the same. Physical observation of the developed 
formulations showed phase separation after addition of 20% 
glycerol, while the formulation having 0-15% glycerol showed 
uniformity in the texture and no phase separation was observed. On 
the other hand addition of ethanol up to 4% showed no effect on the 
texture of the formulation. Addition of ethanol (0-4%), and glycerol 
(0-20%) in normal ringer lactate also prevents cryo-degradation of 
the formulations which resists to freezing at subzero temperature 
[25]. As shown in table 2, formulation containing 4% ethanol with 
15% (F-13) and 20% (F-14) glycerol has the highest freezing 
resistant property and takes maximum time to freeze out and 
minimum for thawing. As reported earlier intravenous formulations 
containing more than 2% ethanol and 15% glycerol showed toxicity 
[26, 27]. In view of that, formulation F-10 (containing 2% ethanol, 
and 15% glycerol) was considered to be the best and chosen for 
further safety and efficacy studies. In addition to depression in 
freezing point, developed formulation also provides crystalloid 
solution and additional energy by means of glycerol. Stability of the 
formulation was evaluated by microscopic examination and 
confirmed as no aggregation and no variation in pH was found. 
Infusion of large quantities of blood can increase mortality or result 
in serious complications, such as disseminated intravascular 
coagulation (DIC), acute respiratory distress syndrome (ARDS), or 
systemic inflammatory response syndrome (SIRS) to the exposing 
patients [28, 29]. 
Efficacy evaluation of developed FRIV formulation was carried out 
by induction of hemorrhagic shocks in experimental animal models 
(Swiss albino strain mice). As shown in Figure 1, developed FRIV 
fluid formulation was found to be more effective in terms of survival 
rate (75%) of animals as compared to ringer lactate infused animals 
(25%), while no survival was observed in case of control (group I) 
animals. A large volume of fluids occasionally must be administered 
repeatedly by the intravenous route to test the safety and 
tolerability studies of a product. Therefore it is important for 
pathologists, toxicologists, and investigators to be aware of all 
mortalities, clinical signs, time of onset, duration, and reversibility of 
toxicity produced by intravenous infusions of large volume of 
formulations. Other properties of the solution or suspension, such as 
pH, irritancy, pharmacologic effects, and systemic toxicity, may also 
affect the maximal tolerated volume and rate of infusion of a 
particular fluid. 
Safety studies of the developed formulation were carried by means 
of the toxicological evaluation using standard techniques like 
pathological studies, hematological analysis, serum biochemistry etc. 
[30-34]. No sign of local injury and inflammatory response was 
observed at site of injection in the treated groups of animals. As 
shown in Table 3, hemogram was estimated and results showed no 
deleterious effect on blood cell count, hemoglobin and other related 
parameters. Liver is the vital organ of paramount importance 
involved in the maintenance of metabolic function and detoxification 
of drugs. The fluid infused eliminates through renal excretion. Thus 
it was mandatory to estimate its effects on kidney and liver 
functions. 
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Transaminases (AST and ALT), ALP, creatinine and uric acid are 
generally used as an indicator for liver and kidney toxicity [35, 36]. 
No significant change was found in serum levels of AST, ALT, and 
ALP enzymes post intravenous infusion of formulation showing no 
detrimental effect on liver and kidney as shown in Table 4. Similarly, 
no significant change in the organic body weight of the FRIV treated 
animals were observed in comparison to the control group animals 
as shown in Figure 3. The safety of formulation on specific organs 
was further confirmed by histopathological assessment. 
Histopathological examination of selected vital organs (heart, lung, 
liver, kidney, and spleen) from both treated and control animals 
showed normal architecture, suggesting that no microscopic 
changes and morphological disturbances were caused due to an 
infusion of fluid at all dose levels. The fluid volumes used in current 
study were taken large as small animals require higher doses per kg 
body weight than larger animals due to their higher metabolic rate 
[37]. However, we did not examine the potential adverse effects of 
long-term repeated intravenous infusion of large fluid volumes or 
possible changes in many clinical laboratory parameters. The 
infusion rates used in this study were considerably below the 
estimated glomerular filtration rate of mice, suggesting that 
infusions of large volumes at higher rates may be possible. 
Limitations 
The developed freezing resistant formulation presented in this study 
is in the pre-clinical stage and need to be further evaluation for its 
safety and efficacy. The developed formulation can be used in 
emergency conditions if found safe in further clinical studies. The 
long term stability and sterility of the formulation is also required to 
assess for its long term storage so that it can be used in case of 
emergency. 
CONCLUSION 
Our results confirmed that developed and optimized formulation has 
the freezing resistant characteristic and it takes more time to freeze 
out and less time in thawing in comparison to standard ringer 
lactate fluid. Physiochemical characterization confirmed stability 
and sterility of the developed intravenous formulation. Enhanced 
survival rate (75%) of the small experimental animals induced with 
hemorrhagic shock confirmed the efficacy of FRIV formulation. An 
acute toxicity study of developed formulation indicates no adverse 
clinical effects in mice when administered intravenously at volumes 
up to 40 ml/kg and at rates up to 4 ml/h. In conclusion, our data 
suggest that developed FRIV formulation is efficient, safe and 
indicates no clinically relevant alterations of any of physiological, 
biochemical and histopathological parameters. Developed FRIV 
formulation can use as lifesaving and possessing widely clinical 
application and worth for wide use in emergency at high altitude. 
CONFLICTS OF INTERESTS 
Authors declare that there are no conflicts of interest. 
ACKNOWLEDGEMENT 
Authors are thankful to Defence Research and Development 
Organization, Ministry of Defence, Government of India for 
providing the funds to carry out this work. 
REFERENCES 
1. Dutton RP. Resuscitative strategies to maintain homeostasis 
during damage control surgery. Br J Surg. 2012;99(1):21-8. 
2. Moore FA, McKinley BA, Moore EE. The next generation in 
shock resuscitation. Lancet 2004;363:1988-96. 
3. Hak DJ, Smith WR, Suzuki T. Management of hemorrhage in 
life-threatening pelvic fracture. J Am Acad Orthop Surg 
2009;17(7):447-57. 
4. Gutierrez G, Reines HD, Wulf-Gutierrez ME. Clinical review: 
hemorrhagic shock. Crit Care 2004;8(5):373-81. 
5. Letson HL, Dobson GP. Unexpected 100% survival following 
60% blood loss using small-volume 7.5% NaCl with adenocaine 
and Mg++ in the rat model of extreme hemorrhagic shock. 
Shock 2011;36(6):586-94. 
6. Rönn T, Lendemans S, de Groot H, Petrat F. A new model of 
severe hemorrhagic shock in rats. Comp Med 2011;61(5):419-
26. 
7. Wenzel V, Raab H, Dunser MW. Arginine vasopressin: a 
promising rescue drug in the treatment of uncontrolled 
haemorrhagic shock. Best Pract Res Clin Anaesthesiol 
2008;22(2):299-16. 
8. Committee on Trauma, Shock. Advanced Trauma Life Support, 
Student Course Manual, 6th
9. Jordan KS. Fluid resuscitation in acutely injured patients. J 
Intraven Nurs 2000;23(2):81-7. 
 ed. Chicago: American College of 
Surgeons; 1997. p. 87-107. 
10. Martel MJ, MacKinnon KJ, Arsenault MY. Arsenault, 
Hemorrhagic shock. J Obstet Gynaecol Can 2002;24(6):504-20. 
11. Shires GT, Browder LK, Steljes TP, Williams SJ, Browder TD, 
Barber AE. The effect of shock resuscitation fluids on apoptosis. 
Am J Surg 2005;189:85-91. 
12. Waitt C, Waitt C, Pirmohamed M. Intravenous therapy. PGD 
Med J 2004;80:1-6. 
13. Tjon JA, Ansani NT. Transdermal nitroglycerin for the 
prevention of intravenous infusion failure due to phlebitis and 
extravasation. Ann Pharmacother 2000;34:1188-92. 
14. Schrier RW. The science behind hyponatremia and its clinical 
manifestations. Pharmacotherapy 2011;31(5):9S-17S. 
15. Cook LS. IV fluid resuscitation. J Infus Nurs 2003;26(5):296-303. 
16. Tremblay LN, Rizoli SB, Brenneman FD. Advances in fluid 
resuscitation of hemorrhagic shock. Can J Surg 
2001;44(3):172-9. 
17. Kaplan LJ, Philbin N, Arnaud F, Rice J, Dong F, Freilich D. 
Resuscitation from hemorrhagic shock: fluid selection and 
infusion strategy drives unmeasured ion genesis. J Trauma 
2006;61(1):90-8. 
18. Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, 
Lewin NA, Nelson LS. Goldfrank's Toxicologic Emergencies, 8th 
ed. McGraw-Hill Professional; 2006. 
19. Moore EE, Johnson JL, Cheng AM, Masuno T, Banerjee A. 
Insights from studies of blood substitutes in trauma. Shock 
2005;24(3):197-205. 
20. Olson H, Betton G, Robinson D. Concordance of the toxicity of 
pharmaceuticals in humans and animals. Regul Toxicol 
Pharmacol 2000;32(1):56-7. 
21. Slaoui M, Fiette L. Histopathology procedures: from tissue 
sampling to histopathological evaluation. Methods Mol Biol 
2011;691:69-82. 
22. Kiernan JA. Histological and Histochemical Methods. Theory 
and Practice. 4th ed. Bloxham,UK: Scion; 2009. p. 12-73. 
23. Hierholzer C, Billiar TR. Molecular mechanisms in the early 
phase of hemorrhagic shock. Langenbecks Arch Surg 
2001;386(4):302-08. 
24. Rhee P, Koustova E, Alam HB. Searching for the optimal 
resuscitation method: recommendations for the initial fluid 
resuscitation of combat casualties. J Trauma 2003;54(5):S52-S4. 
25. Kumana CR, Chan GTC, Yu YL. Investigation of intravascular 
haemolysis during treatment of acute stroke with intravenous 
glycerol. Br J Clin Pharm 1994;29:347-53. 
26. Nau R, Prins FJ, Kolenda H, Prange HW. Temporary reversal of 
serum to cerebrospinal fluid glycerol concentration gradient 
after intravenous infusion of glycerol. Eur J Clin Pharmacol 
1992;42(2):181-5. 
27. Braun LJ, Tyagi A, Perkins S. Development of a freeze-stable 
formulation for vaccines containing aluminum salt adjuvants. 
Vaccine 2009;27:72-9. 
28. Linker CA, McPhee SJ, Papadakis MA. (Eds.), Current Medical 
Diagnosis & Treatment. New York: Lange Medical Boods/ 
McGraw-Hill. 45th ed; 2006. p. 481-535. 
29. Thompson RCC. Physiologic 0.9% saline in the fluid resuscitation of 
trauma. J R Army Med Corps 2005;151(3):146-51. 
30. Baker AJ, Park E, Hare G, Liu, Mazer D. Effects of resuscitation 
fluid on neurological physiology after cerebral trauma and 
hemorrhage. J Trauma 2008;64(2):348-57. 
31. Kiraley LN, Jerome A, Differding. Resuscitation with normal 
saline (ns) vs. lactated ringer’s (lr). modulates 
hypercoagulability and leads to increased blood loss in an 
Amit et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 10, 490-496 
496 
uncontrolled hemorrhagic shock swine model. J Trauma 
2006;61:57-65. 
32. Koustova E, Stanton K, Guschin V, Alam AB, Stegalkina S, Rhee 
PM. Effects of lactated Ringer’s solutions on human leukocytes. 
J Trauma 2002;52:872-8. 
33. Todd SR, Malinoski D, Muller PJ, Schreiber MA. Lactated 
ringer’s is superior to normal saline in resuscitation of 
uncontrolled hemorrhagic shock. J Trauma 2007;62:636-9. 
34. Waters JH, Gottlieb A, Schoenwald. Normal saline versus 
lactated ringer’s solution for intraoperative fluid management 
in patients undergoing abdominal aortic aneurysm repair: an 
outcome study. Anesth Analg 2001;93:817-22. 
35. Hayes AW. Principles and Methods of Toxicology. 5th ed. 
Informa Health care, New York; 2007. 
36. Raza M, Al-Shabanah OA, El-Hadiyah TM. Effect of prolonged 
vigabatrin treatment on hematological and biochemical 
parameters in plasma, liver and kidney of swiss albino mice. Sci 
Pharm 2002;70:135-46. 
37. Olsson J, Hahn RG. Glycine toxicity after high-dose I. V. infusion 
of 1.5% glycine in the mouse. Br J Anaesth 1999;82(2):250-4.
 
